Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.3 - Pfizer Inc. - Amendment

5 Nov 2015 15:35

RNS Number : 7517E
JPMorgan Asset Management
05 November 2015
Β 

Β 

Β 

AMENDMENT

FORM 8.3

Β 

IRISH TAKEOVER PANEL

Β 

Β 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2007 (AS AMENDED)

Β 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Β 

Β 

1. KEY INFORMATION

Β 

Name of person dealing (Note 1)

JPMorgan Asset Management

Company dealt in

Pfizer Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary Shares

Date of dealing

03 November 2015

Β 

Β 

2. INTERESTS AND SHORT POSITIONSΒ 

Β 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Β 

Β 

Β 

Long

Short

Β 

Β 

Number

(%)

Number

(%)

(1) Relevant securities

Β 

85,733,972 *

1.39

(2) Derivatives (other than options)

Β 

208,388

0.00

(3) Options and agreements to purchase/sell

Β 

Total

Β 

85,942,360 *

1.39

*In addition to the dealings in section 3, there is a reduction in the holding of 356 shares due to a transfer.

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Β 

Class of relevant security:

Β 

Long

Short

Β 

Β 

Number

(%)

Number

(%)

(1) Relevant securities

Β 

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Β 

Total

Β 

Β 

Β 

Β 

Β 

3. DEALINGS (Note 4)

Β 

(a) Purchases and sales

Β 

Purchase/sale

Β 

Number of relevant securities

Price per unit

(USD)

Purchase

Purchase

Β 

Sale

Sale

Sale

1,469

11

Β 

2,492

76,340

15

34.7195 USD

34.9900 USD

Β 

34.7446 USD

34.9214 USD

35.0200 USD

Β 

Β 

Β 

Β 

Β 

(b) Derivatives transactions (other than options transactions)

Β 

Product name,

e.g. CFD

Nature of transaction (Note 6)

Number of relevant securities (Note 7)

Price per unit (Note 5)

Β 

Β 

Β 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Β 

Product name,

e.g. call option

Β 

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise

price

Type, e.g. American, European etc.

Expiry

date

Option money

paid/received per unit (Note 5)

Β 

Β 

(ii) Exercising

Β 

Product name, e.g. call option

Number of securities

Exercise price per unit (Note 5)

Β 

Β 

Β 

Β 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Β 

Nature of transaction (Note 8)

Β 

Details

Price per unit (if applicable) (Note 5)

Β 

Β 

Β 

Β 

Β 

4. OTHER INFORMATION

Β 

Agreements, arrangements or understandings relating to options or derivatives

Β 

Β 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Β 

Β 

Β 

Β 

Is a Supplemental Form 8 attached? (Note 9)

NO

Β 

Date of disclosure

05 November 2015

Contact name

Evangelos Galiatsatos

Telephone number

0207 742 6148

If a connected EFM, name of offeree/offeror with which connected

N/A

If a connected EFM, state nature of connection (Note 10)

N/A

Β 

Β 

Β 

The Notes on Form 8.3 can be viewed on the Panel's website at www.irishtakeoverpanel.ie.Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEFSIFIIFISEDF
Date   Source Headline
4th Nov 20155:37 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:37 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:35 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20155:34 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20153:33 pmRNSForm 8.3 - Allergan plc
4th Nov 20153:30 pmRNSForm 8.3 - Pfizer Inc. - Amendment
4th Nov 20153:29 pmRNSForm 8.3 - Pfizer Inc.
4th Nov 20153:26 pmRNSForm 8.3 - Pfizer Inc.
4th Nov 20153:20 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20153:20 pmRNSForm 8.3 - PFIZER INC
4th Nov 20153:18 pmRNSRule 38.5 - Replacement Pfizer INC
4th Nov 20153:17 pmRNSForm 8.3 - ALLERGAN PLC
4th Nov 20153:07 pmBUSForm 8.3 - Pfizer Inc.
4th Nov 20153:06 pmRNSForm 8.3 - Pfizer Inc
4th Nov 20152:54 pmRNSForm 8.3 - Pfizer, Inc.
4th Nov 20152:27 pmRNSForm 8.3 - Pfizer Inc
4th Nov 20151:20 pmRNSForm 8.1 - [Pfizer Inc]
4th Nov 20151:16 pmRNSForm 38.5a
4th Nov 20151:13 pmRNSForm 38.5b
4th Nov 20151:12 pmRNSForm 38.5b
4th Nov 201512:03 pmRNSForm 38.5(b) - Pfizer Inc.
4th Nov 201511:55 amRNSForm 8.3 - Pfizer Inc.
4th Nov 201511:42 amRNSForm 38.5(a) - Pfizer Inc.
4th Nov 201511:33 amRNSRule 8.1 - Pfizer INC
4th Nov 201511:32 amRNSRule 38.5 - Pfizer INC
4th Nov 201511:32 amRNSRule 38.5 - Pfizer INC
4th Nov 201511:31 amRNSRule 38.5 - Pfizer INC
3rd Nov 20156:04 pmRNSForm 38.5a
3rd Nov 20156:02 pmRNSForm 38.5b
3rd Nov 20156:01 pmRNSForm 8.1 - [Pfizer]
3rd Nov 20155:57 pmRNSForm 8.1 - [Pfizer]
3rd Nov 20155:55 pmRNSForm 38.5b
3rd Nov 20153:49 pmRNSForm 8.3 - Allergan plc
3rd Nov 20153:31 pmRNSForm 8.3 - Pfizer Inc
3rd Nov 20153:20 pmRNSForm 8.3 - [PFIZER INC]
3rd Nov 20153:15 pmRNSForm 8.3 - Pfizer, Inc.
3rd Nov 20153:00 pmRNSForm 8.3 - PFIZER INC
3rd Nov 20152:59 pmRNSForm 8.3 - ALLERGAN PLC
3rd Nov 20152:57 pmRNSForm 8.3 - Pfizer Inc. - Amendment
3rd Nov 20152:55 pmRNSForm 8.3 - Pfizer Inc.
3rd Nov 20152:35 pmRNSForm 8.3 - Pfizer Inc
3rd Nov 20152:32 pmBUSForm 8.3 - Pfizer Inc.
3rd Nov 20152:15 pmRNSForm 8.3 - Allergan Plc
3rd Nov 201512:01 pmRNSForm 38.5(b) - Pfizer Inc.
3rd Nov 201511:56 amRNSRule 38.5 - Pfizer INC
3rd Nov 201511:54 amRNSRule 38.5 - Pfizer INC
3rd Nov 201511:54 amRNSRule 38.5 - Pfizer INC
3rd Nov 201511:09 amRNSForm 38.5(b) - Pfizer Inc.
3rd Nov 201511:08 amRNSForm 38.5(b) - Pfizer Inc.- Amendment
3rd Nov 20157:00 amRNSForm 8.3 - Pfizer, Inc.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.